Attana AB

Equities

ATANA

SE0010547273

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.095 ^SEK	-6.86%		+11.76%	-4.04%

Apr. 30	BioInvent Announces Evaluating Attana Technology	CI
Apr. 25	Attana AB Enters Third Year of A Five-Year Service and Support Contract with A Leading Health Institute in the US	CI

Attana AB Receives A Cell™ 250 Instrument Order from A European Life Science Company

February 17, 2022 at 01:49 am EST

Attana AB has received an order for a Cell™ 250 instrument from a European Life Science company. This is the client's second Attana instrument and is the result of a successful use and the client's growth plans. The Cell™ 250 instrument will be installed during first quarter of 2022 and will positively affect Attana earnings in first quarter of 2022 and cash flow for the remainder of the year.

Latest news about Attana AB

BioInvent Announces Evaluating Attana Technology	Apr. 30	CI
Attana AB Enters Third Year of A Five-Year Service and Support Contract with A Leading Health Institute in the US	Apr. 25	CI
Attana AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Attana Lands Order for Kinetic Interaction Analysis of Tissue in US	Dec. 04	MT
Attana AB Receives Breakthrough Order with New Customer in the USA	Dec. 04	CI
Customer Develops Therapeutic Antibodies Against Cancer and Uses Attana's Cell-Based Technology	Nov. 23	CI
Attana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Attana Announces CEO Changes	23-09-18	CI
Attana AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-29	CI
Attana AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Attana AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
Attana AB Submits International Patent Application	23-02-14	CI
Attana AB and 19 Plus AB Sign Collaboration Agreement of Marketing and Sales of Attana Individual Immunity Profiles	23-02-02	CI
Attana Submits New Patent Application Regarding Neutralizing Effect in Complex Samples	22-12-20	CI
Attana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Attana AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
Attana AB Extends Collaborative Research Agreement with Leading Us Academic Medical Center for Biomedical Research	22-06-23	CI
Attana AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI
Attana AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Attana Submits New Patent Application	22-02-18	CI
Attana AB Receives A Cell™ 250 Instrument Order from A European Life Science Company	22-02-17	CI
Attana and AroCell Initiates Discussion for Collaboration	22-02-09	CI
Attana Signs Collaborative Research Agreement with US Academic Medical Center for Biomedical Research	22-02-04	CI
Attana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Attana and Triolab Sign Distribution Agreement for All Attana Products on the Swedish Market	21-11-18	CI

Chart Attana AB

Duration

Period

More charts

Company Profile

Attana AB is a Sweden-based biotechnology company specializing in in vitro characterization of molecular interactions mimicking in vivo conditions. The Company develops proprietary label-free biosensors, based on the Quartz Crystal Microbalance (QCM) technology, for biochemical, crude, sera and cell-based assays. Its products and research services are used by pharmaceutical and biotechnology companies to quality control the production line of a biological pharmaceutical or gain insight into advanced dynamic features of target molecules, as well as by academic institutions within the life sciences. Attanaâs biosensors are used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
ATTANA AB	-4.04%	3.7M
MIMEDX GROUP, INC.	-10.49%	1.17B
NIBEC CO., LTD.	-21.11%	127M
KIM FOREST ENTERPRISE CO., LTD.	+3.25%	59.36M
NOVACYT	+2.38%	56.25M
BONUS BIOGROUP LTD.	+1.80%	53.81M

Bio Medical Devices